The present invention provides a pharmaceutical composition for treating or preventing a cognitive disease or disorder, comprising a compound represented by Formula (I), an enantiomer thereof a diastereomer thereof, or a pharmaceutically acceptable salt thereof.

The present invention discloses a biaryl urea RORt inhibitor, and specifically relates to a biaryl urea derivative, as represented by formula I, with an RORt inhibiting activity, and a preparation process thereof, and a pharmaceutical composition comprising the compound. Further disclosed is use of the compound for treating an RORt-related disease. ##STR00001##

The present invention discloses a biaryl urea RORt inhibitor, and specifically relates to a biaryl urea derivative, as represented by formula I, with an RORt inhibiting activity, and a preparation process thereof, and a pharmaceutical composition comprising the compound. Further disclosed is use of the compound for treating an RORt-related disease. ##STR00001##

A method of decoloring an ionic liquid includes preparing a discolored ionic liquid, and decoloring the discolored ionic liquid through irradiation with UV rays. An ionic liquid that is discolored due to heat treatment upon purification is decolored and can thus be reused. The method of decoloring the ionic liquid is effective because an ionic liquid, which is discolored due to heat treatment upon purification, can be decolored in a simple manner and also because an ionic liquid, which is discolored and is thus difficult to apply to the purification of an organic material, can be decolored in a simple manner, and can thus be reused in the form of a high-purity ionic liquid.

A method of decoloring an ionic liquid includes preparing a discolored ionic liquid, and decoloring the discolored ionic liquid through irradiation with UV rays. An ionic liquid that is discolored due to heat treatment upon purification is decolored and can thus be reused. The method of decoloring the ionic liquid is effective because an ionic liquid, which is discolored due to heat treatment upon purification, can be decolored in a simple manner and also because an ionic liquid, which is discolored and is thus difficult to apply to the purification of an organic material, can be decolored in a simple manner, and can thus be reused in the form of a high-purity ionic liquid.

The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.

Provided is an actinic ray-sensitive or radiation-sensitive resin composition that can provide a pattern having good cross-sectional rectangularity. The actinic ray-sensitive or radiation-sensitive resin composition includes: a resin having a group that is decomposed by the action of an acid to generate a polar group; an onium salt (I) that generates an acid represented by formula (1) upon irradiation with actinic rays or radiation; and an onium salt (II) having at least one structural moiety W that includes an anionic moiety A and a cationic moiety M and forms an acidic moiety represented by HA upon irradiation with the actinic rays or radiation. The acid dissociation constant derived from the acidic moiety represented by HA and formed by replacing the cationic moiety in the structural moiety W with H.sup.+ is larger than the acid dissociation constant of the acid represented by formula (1).

##STR00001##

The present invention discloses a biaryl urea RORt inhibitor, and specifically relates to a biaryl urea derivative, as represented by formula I, with an RORt inhibiting activity, and a preparation process thereof, and a pharmaceutical composition comprising the compound. Further disclosed is use of the compound for treating an RORt-related disease.

##STR00001##

The present invention relates to novel compounds of general formula (I) wherein the groups X, and R.sup.1 to R.sup.4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.

##STR00001##

The present invention relates to novel compounds of general formula (I) wherein the groups X, and R.sup.1 to R.sup.4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.

##STR00001##